Speciality Medicines IPO was launched through the Book Built SME route by Speciality Medicines Limited. The public offering consisted entirely of a fresh issue of equity shares, while no shares were offered for sale by existing shareholders. The company planned to utilise the funds raised through the public issue to support future business growth, strengthen working capital, and meet general corporate requirements. Following the completion of the IPO process, the company’s equity shares were listed on the BSE SME platform.
Speciality Medicines Limited operates in the pharmaceutical distribution and healthcare supply industry. The company is engaged in the procurement, marketing, and distribution of pharmaceutical products and speciality medicines across different therapeutic categories. Its business focuses on ensuring the availability of medicines through an organised supply and distribution network.
The company supplies pharmaceutical products to hospitals, healthcare institutions, pharmacies, distributors, and other healthcare providers. Its operations include procurement, inventory management, warehousing, logistics, distribution, and customer support to ensure timely product availability.
The company continues to strengthen its distribution capabilities by expanding its product portfolio, improving supply chain efficiency, adopting better inventory management practices, and developing long-term business relationships across the healthcare sector.
India’s pharmaceutical industry continues to experience steady growth due to increasing healthcare awareness, rising demand for quality medicines, expanding healthcare infrastructure, higher medical spending, and continuous development of pharmaceutical products. These industry trends continue to support long-term opportunities for pharmaceutical distribution businesses.
Since the IPO has already been completed and the shares are listed, investors should carefully evaluate the company’s financial performance, business model, operational efficiency, competitive position, and future growth prospects before making an investment decision.
Speciality Medicines IPO Details
| IPO Details | Information |
|---|---|
| IPO Name | Speciality Medicines IPO |
| Company Name | Speciality Medicines Limited |
| IPO Type | Book Built Issue |
| IPO Category | SME IPO |
| Face Value | ₹10 Per Equity Share |
| Price Band | ₹117 to ₹124 Per Share |
| Issue Size | ₹29.14 Crore |
| Fresh Issue | ₹29.14 Crore |
| Offer for Sale | Nil |
| Total Shares Offered | 23,50,000 Equity Shares |
| IPO Open Date | 20 March 2026 |
| IPO Close Date | 24 March 2026 |
| Basis of Allotment | 25 March 2026 |
| Refund Initiation | 27 March 2026 |
| Shares Credited to Demat Account | 27 March 2026 |
| Listing Date | 30 March 2026 |
| Listing Exchange | BSE SME |
| Lot Size | 1,000 Equity Shares |
| Registrar | Skyline Financial Services Private Limited |
| Book Running Lead Manager | Unistone Capital Private Limited |
The IPO consisted entirely of a fresh issue of equity shares. The company proposed to utilise the proceeds for business expansion, working capital requirements, and general corporate purposes.
Speciality Medicines IPO Dates
The important milestones relating to the Speciality Medicines IPO are provided below.
| IPO Event | Date |
|---|---|
| IPO Opening Date | 20 March 2026 |
| IPO Closing Date | 24 March 2026 |
| Basis of Allotment | 25 March 2026 |
| Refund Initiation | 27 March 2026 |
| Shares Credited to Demat Account | 27 March 2026 |
| Listing Date | 30 March 2026 |
After completion of the allotment process, successful applicants received the allotted equity shares in their demat accounts before trading commenced on the BSE SME platform.
Speciality Medicines IPO Reservation
The equity shares offered through the IPO were reserved among different categories of investors according to the applicable SME IPO allocation framework.
| Investor Category | Reservation |
|---|---|
| Qualified Institutional Buyers (QIB) | Not More Than 50% |
| Non-Institutional Investors (NII) | Not Less Than 15% |
| Retail Individual Investors (RII) | Not Less Than 35% |
The final allocation under each investor category depended upon the number of valid applications received during the subscription period.
Speciality Medicines IPO Lot Size
Applications for the IPO were accepted only in the prescribed lot sizes.
| Application | Shares | Amount |
|---|---|---|
| Retail Minimum | 2 Lots (2,000 Shares) | ₹2,48,000 |
| Retail Maximum | 2 Lots (2,000 Shares) | ₹2,48,000 |
| HNI Minimum | 3 Lots (3,000 Shares) | ₹3,72,000 |
The application values shown above are calculated using the upper price band of ₹124 per equity share.
About Speciality Medicines Limited
Speciality Medicines Limited operates in the pharmaceutical distribution and healthcare supply sector. The company is engaged in the procurement, marketing, distribution, and supply of pharmaceutical products and speciality medicines across multiple therapeutic categories. Its business focuses on ensuring the timely availability of healthcare products through an organised distribution network that serves hospitals, pharmacies, healthcare institutions, distributors, and other medical service providers.
The company combines procurement expertise, inventory management, warehousing, logistics, and distribution capabilities to deliver pharmaceutical products efficiently. By maintaining a diversified product portfolio and an organised supply chain, it supports healthcare providers with consistent product availability.
Business Operations
Speciality Medicines Limited carries out various activities across the pharmaceutical distribution business to ensure efficient procurement, storage, and delivery of healthcare products.
- Pharmaceutical Distribution – The company distributes pharmaceutical products and speciality medicines across different therapeutic segments.
- Healthcare Supply Chain – Its operations include procurement, warehousing, inventory management, transportation, and product delivery through an organised supply network.
- Hospital Supply Services – The company supplies pharmaceutical products to hospitals, healthcare institutions, clinics, and medical service providers.
- Pharmacy Distribution – It supplies medicines to retail pharmacies, wholesalers, and authorised pharmaceutical distributors.
- Inventory Management – Efficient inventory planning helps maintain product availability while supporting smooth day-to-day operations.
- Logistics and Warehousing – The company manages storage, handling, and transportation of pharmaceutical products while maintaining appropriate quality standards.
- Product Portfolio Expansion – Continuous addition of pharmaceutical products enables the company to serve a broader customer base across different healthcare segments.
- Customer Relationship Management – Long-term relationships with customers and suppliers support business continuity and operational stability.
- Regulatory Compliance – Business operations are carried out in accordance with applicable pharmaceutical distribution standards and regulatory requirements.
- Operational Efficiency – The company continues to improve supply chain management, inventory control, and distribution processes to enhance overall business performance.
Industry Overview
India’s pharmaceutical industry continues to expand with rising healthcare awareness, increasing demand for medicines, growing healthcare infrastructure, higher healthcare spending, and continuous development of pharmaceutical products. Growth in hospitals, diagnostic centres, specialty healthcare services, and organised pharmaceutical distribution continues to create long-term opportunities for companies operating in the healthcare supply chain.
The increasing demand for speciality medicines, chronic disease management, advanced healthcare treatments, and wider access to medical services continues to support the growth of pharmaceutical distribution businesses across the country.
Business Strategy
Speciality Medicines Limited aims to strengthen its position by expanding its distribution network, increasing its product portfolio, improving supply chain efficiency, strengthening inventory management systems, and enhancing customer relationships. The company also focuses on operational improvements that support efficient procurement, storage, and timely delivery of pharmaceutical products.
Through continuous investment in distribution infrastructure, technology, operational efficiency, and business development, the company seeks to expand its market presence, improve service quality, and achieve sustainable long-term business growth.
Speciality Medicines IPO Financial Information
A company’s financial performance provides valuable insights into its revenue growth, profitability, operational efficiency, and financial stability. Reviewing financial statements over multiple years helps investors understand how the business has expanded and how efficiently it has generated earnings from its operations.
Speciality Medicines Financial Summary
| Particulars | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue from Operations | ₹221.64 Crore | ₹278.53 Crore | ₹346.87 Crore |
| Total Income | ₹222.18 Crore | ₹279.41 Crore | ₹348.02 Crore |
| EBITDA | ₹13.86 Crore | ₹17.74 Crore | ₹22.96 Crore |
| Profit Before Tax (PBT) | ₹9.81 Crore | ₹12.54 Crore | ₹16.68 Crore |
| Profit After Tax (PAT) | ₹7.31 Crore | ₹9.35 Crore | ₹12.43 Crore |
| Net Worth | ₹31.82 Crore | ₹41.17 Crore | ₹53.61 Crore |
| Total Borrowings | ₹18.74 Crore | ₹20.43 Crore | ₹19.26 Crore |
The company has reported steady growth in revenue and profitability over the last three financial years. Revenue has increased consistently, reflecting expansion in business operations and growing demand for pharmaceutical products. Profitability has also improved during the same period, indicating better operational efficiency and disciplined cost management. The increase in net worth highlights the company’s strengthening financial position, while borrowings have remained at manageable levels. Investors should evaluate these financial results together with future business plans, industry outlook, and valuation before making an investment decision.
Speciality Medicines IPO Key Performance Indicators (KPIs)
Key Performance Indicators help investors evaluate the company’s profitability, capital efficiency, financial strength, and overall operating performance. These financial ratios provide additional insights into how effectively the company utilises its resources to generate returns.
| KPI | Value |
|---|---|
| Return on Equity (ROE) | 27.96% |
| Return on Capital Employed (ROCE) | 23.81% |
| Return on Net Worth (RONW) | 23.19% |
| EBITDA Margin | 6.60% |
| PAT Margin | 3.58% |
| Debt-to-Equity Ratio | 0.36 |
| Earnings Per Share (EPS) | ₹8.18 |
| Net Asset Value (NAV) Per Share | ₹35.59 |
| Price to Earnings (P/E) | 15.16x |
The financial ratios indicate stable profitability, efficient utilisation of capital, and a balanced financial structure. Return ratios reflect the company’s ability to generate earnings from shareholders’ funds, while operating margins demonstrate consistent business performance. Investors should consider these financial indicators together with the company’s distribution network, operational capabilities, competitive position, and long-term growth prospects before making an investment decision.
Objects of the Speciality Medicines IPO
The company proposed to utilise the net proceeds from the fresh issue for the following purposes:
- Meeting additional working capital requirements.
- Expanding business operations and distribution capabilities.
- Strengthening warehousing, inventory management, and supply chain infrastructure.
- General corporate purposes.
The planned utilisation of the IPO proceeds is expected to support business expansion, improve operational efficiency, strengthen distribution capabilities, and provide greater financial flexibility for future growth.
Speciality Medicines IPO Listing Performance
The listing performance shows how the company’s shares traded when they were first listed on the stock exchange after the completion of the IPO. While listing gains may indicate positive initial market sentiment, long-term investment performance depends on business growth, financial strength, operational efficiency, and future expansion.
| Particular | Value |
|---|---|
| Listing Exchange | BSE SME |
| Listing Date | 30 March 2026 |
| Issue Price | ₹124 Per Share |
| Listing Price | ₹141.20 Per Share |
| Listing Gain | ₹17.20 Per Share |
| Listing Gain (%) | 13.87% |
Speciality Medicines Limited made a positive debut on the BSE SME platform by listing above its issue price. Although the shares delivered a listing premium, investors should evaluate the company’s long-term financial performance and business prospects before making investment decisions.
Speciality Medicines IPO Subscription Status
The subscription details indicate the level of investor participation received during the IPO bidding period. While strong subscription often reflects positive market interest, investment decisions should also be based on the company’s financial performance, valuation, and long-term business outlook.
Speciality Medicines IPO Subscription
| Investor Category | Subscription |
|---|---|
| Qualified Institutional Buyers (QIB) | 91.84 Times |
| Non-Institutional Investors (NII) | 203.57 Times |
| Retail Individual Investors (RII) | 147.92 Times |
| Total Subscription | 138.46 Times |
The IPO witnessed strong participation across all investor categories. Non-institutional investors recorded the highest subscription level, while qualified institutional buyers and retail investors also showed healthy interest during the bidding period.
Speciality Medicines IPO Review
Speciality Medicines Limited operates in the pharmaceutical distribution and healthcare supply sector by supplying pharmaceutical products and speciality medicines through an organised distribution network. The company serves hospitals, healthcare institutions, pharmacies, distributors, and other healthcare providers across multiple therapeutic segments.
Its business operations include procurement, inventory management, warehousing, logistics, product distribution, and customer support. A well-organised supply chain enables the company to maintain product availability while supporting efficient distribution across its customer network.
The company has reported steady improvement in revenue, profitability, and net worth over recent financial years, reflecting business expansion and improving operational performance. Growth in India’s healthcare industry and increasing demand for pharmaceutical products also support future business opportunities.
However, investors should also consider factors such as industry competition, regulatory changes, working capital requirements, customer concentration, and supply chain risks before making an investment decision.
Overall, Speciality Medicines Limited operates in an industry supported by growing healthcare demand and expanding pharmaceutical consumption. Investors should carefully evaluate the company’s financial performance, valuation, business strategy, and future growth opportunities before investing.
Speciality Medicines IPO Strengths
Speciality Medicines Limited has established its business through an organised pharmaceutical distribution network and efficient supply chain management.
- Diversified Product Portfolio – The company distributes pharmaceutical products and speciality medicines across multiple therapeutic categories.
- Established Distribution Network – Its supply network serves hospitals, healthcare institutions, pharmacies, and pharmaceutical distributors.
- Efficient Supply Chain Management – Strong inventory control, warehousing, and logistics support timely product availability.
- Consistent Financial Growth – Revenue, profitability, and net worth have shown steady improvement over recent financial years.
- Growing Healthcare Industry – Increasing demand for pharmaceutical products and healthcare services continues to create long-term business opportunities.
- Operational Focus – Continuous improvement in procurement, inventory management, and distribution processes supports business efficiency.
Speciality Medicines IPO Risk Factors
Every pharmaceutical distribution business is exposed to operational and industry-related risks. Investors should carefully evaluate the following factors before making an investment decision.
- Regulatory Compliance – The pharmaceutical industry is subject to various regulatory requirements that may influence business operations.
- Competitive Market – The company operates in a competitive pharmaceutical distribution industry with several organised participants.
- Working Capital Requirements – Distribution businesses require continuous investment in inventory and day-to-day operations.
- Supply Chain Dependence – Delays in procurement, transportation, or product availability may affect business performance.
- Customer Concentration Risk – Dependence on major customers or healthcare institutions may influence future revenue if demand changes.
- Healthcare Industry Changes – Government policies, pricing regulations, and changes in pharmaceutical demand may affect future business growth.
Speciality Medicines IPO Promoters
Speciality Medicines Limited is promoted by experienced professionals associated with the pharmaceutical distribution and healthcare industry. The promoters have contributed to the company’s growth by strengthening its distribution network, expanding business operations, improving supply chain management, and building long-term relationships with customers and suppliers.
Speciality Medicines IPO Promoters Details
| Promoter | Designation |
|---|---|
| Chirag Shah | Promoter & Managing Director |
| Bhavna Shah | Promoter |
Speciality Medicines IPO Management Team
The company is managed by professionals with experience in pharmaceutical distribution, finance, operations, inventory management, supply chain management, and corporate governance. The management team focuses on improving operational efficiency, expanding the product portfolio, strengthening distribution capabilities, and supporting sustainable business growth.
| Name | Designation |
|---|---|
| Chirag Shah | Managing Director |
| Bhavna Shah | Whole-Time Director |
| Amit Mehta | Chief Financial Officer |
| Priya Shah | Company Secretary & Compliance Officer |
Speciality Medicines IPO Registrar Details
The registrar was responsible for processing IPO applications, finalising the basis of allotment, crediting shares to successful applicants, initiating refunds, and handling investor-related services during the public issue process.
| Particular | Details |
|---|---|
| Registrar Name | Skyline Financial Services Private Limited |
| Website | https://www.skylinerta.com |
| IPO Allotment Status | https://www.skylinerta.com/ipo.php |
| Email ID | [email protected] |
| Contact Number | +91-11-4045 0193 |
Speciality Medicines IPO Lead Manager Details
The Book Running Lead Manager coordinated the public issue, managed regulatory compliance, and assisted the company throughout the IPO process.
| Particular | Details |
|---|---|
| Lead Manager | Unistone Capital Private Limited |
| Website | https://www.unistonecapital.com |
| Email ID | [email protected] |
| Contact Number | +91-22-4925 7000 |
Speciality Medicines Limited Contact Details
| Particular | Details |
|---|---|
| Company Name | Speciality Medicines Limited |
| Registered Office | Mumbai, Maharashtra, India |
| Website | https://www.specialitymedicine.com |
| Email ID | [email protected] |
How to Check Speciality Medicines IPO Allotment Status
Investors could check the IPO allotment status after the basis of allotment was finalised through either the registrar’s website or the BSE IPO portal.
Through Skyline Financial Services Private Limited
- Visit the official Skyline Financial Services IPO allotment portal.
- Select Speciality Medicines IPO from the available IPO list.
- Choose PAN Number, Application Number, or DP/Client ID.
- Enter the required details correctly.
- Click Submit to view the allotment status.
Through BSE
- Visit the official BSE IPO allotment page.
- Select Speciality Medicines IPO from the IPO list.
- Enter your PAN Number or Application Number.
- Complete the verification process if required.
- Click Search to check the allotment status.
Frequently Asked Questions (FAQs)
What is the Speciality Medicines IPO?
Speciality Medicines IPO was a Book Built SME public issue consisting entirely of a fresh issue of equity shares.
What was the price band of the Speciality Medicines IPO?
The IPO was offered at a price band of ₹117 to ₹124 per equity share.
What was the total issue size of the Speciality Medicines IPO?
The total issue size was ₹29.14 crore.
When did the Speciality Medicines IPO open and close?
The IPO opened on 20 March 2026 and closed on 24 March 2026.
On which stock exchange are Speciality Medicines shares listed?
The company’s equity shares are listed on the BSE SME platform.
Who was the registrar for the Speciality Medicines IPO?
Skyline Financial Services Private Limited acted as the registrar to the issue.
Who was the lead manager for the Speciality Medicines IPO?
Unistone Capital Private Limited served as the Book Running Lead Manager.
What was the minimum lot size for the Speciality Medicines IPO?
The minimum application size was 2 lots consisting of 2,000 equity shares.
What does Speciality Medicines Limited do?
The company is engaged in the procurement, marketing, distribution, and supply of pharmaceutical products and speciality medicines through an organised healthcare distribution network.
What were the objectives of the Speciality Medicines IPO?
The IPO proceeds were proposed to be utilised for working capital requirements, business expansion, strengthening distribution infrastructure, and general corporate purposes.
